Today: 30 June 2026
Browse Category

Health News 25 January 2026 - 2 June 2026

Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax shares dropped hard Tuesday, despite positive late-stage trial results for its obefazimod drug. Investors focused on reported cancer and dysplasia cases in patients on the higher dose. The stock traded at 63.10 euros on Euronext Paris, well below Monday’s closing price of 111.80 euros, after touching 62.80 euros earlier. Over in the U.S., its Nasdaq ADRs were last at $72.86, down some 44% late in the session. Abivax had turned into one of Europe’s biggest biotech bets, as most of its price depended on obefazimod’s prospects as an oral ulcerative colitis drug. Reuters said its shares led the drop on Europe’s STOXX 600 in Paris this morning. The stock had surged over 16 times last year.
2 June 2026
····
Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics Inc. shares jumped in heavy U.S. trading on Tuesday after the molecular diagnostics company said it had completed a strategy for a possible Ebola assay tied to the Bundibugyo virus outbreak in the Democratic Republic of Congo and Uganda. The stock was recently up 51% at $2.07, after touching $2.73, on volume above 94 million shares; the iShares Russell 2000 exchange-traded fund, a small-cap stock basket, was down about 1.2%. The announcement matters now because the outbreak has moved quickly from a regional health alert to a global market-watched event. Co-Diagnostics said the assay would be linked to its Co-Dx PCR point-of-care platform; PCR, or polymerase chain reaction, is a method that amplifies genetic material so tiny traces of a virus can be detected. CEO Dwight Egan said the company would be “well positioned to execute the strategy” if needed, though the company also said the platform and related tests remain under regulatory review and are not yet available for sale.
19 May 2026
···
GeoVax moves higher before the bell as traders watch for Mpox vaccine news

GeoVax moves higher before the bell as traders watch for Mpox vaccine news

• GeoVax shares rallied in pre-market after closing Friday at $1.23.• The move follows last week’s Q1 update, with no new results from the clinic.• Cash burn, trial timelines and dilution remain key concerns. GeoVax Labs Inc. shares were up before the bell Monday, after the stock took a hit last week. The micro-cap vaccine company was shown at $2.34 by Benzinga at 6:45 a.m. EDT, then quoted at $2.61 on Public.com at 7:00 a.m. ET. GeoVax closed at $1.23. Pre-market action before 9:30 a.m. tends to be thin.
18 May 2026
·
REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Inc. stock dropped Thursday, despite the company reporting that its experimental gene therapy for Duchenne muscular dystrophy hit the primary endpoint in a late-stage trial. Investors zeroed in on lingering safety issues and a murky regulatory path forward, eclipsing the positive trial result. This isn’t just another data release. RGX-202 sits at the core of the Rockville, Maryland biotech’s pipeline, and investors are closely tracking whether it can carve out a place in Duchenne gene therapy—a space already shadowed by liver-safety worries.
14 May 2026
····
SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

Shares of SELLAS Life Sciences climbed in after-hours action Tuesday, following the company’s update that its Phase 3 REGAL trial in acute myeloid leukemia has now logged 78 out of the 80 patient deaths required for the final analysis. In this pivotal study, patient death is the event that triggers the survival analysis. The 80th event triggers what’s known as database lock—a last sweep through the data ahead of analysis. From there: blinded review, stats work, unblinding, and then SELLAS reports the topline readout, that first main batch of results. The company says it still hasn’t seen any trial outcomes.
13 May 2026
···
Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna Inc.’s early-stage hantavirus vaccine programs drew renewed attention Monday after the MV Hondius, a luxury cruise ship, was struck by a fatal Andes virus outbreak—one form of hantavirus known for causing serious lung complications. Countries scrambled to bring home their citizens from the vessel. The outbreak’s timing is crucial—it’s thrust a niche, mostly academic vaccine project into the market limelight right when Moderna is under pressure to show it can generate sales outside its COVID vaccine. Messenger RNA technology, or mRNA, works by telling cells how to manufacture proteins that set off immune defenses.
11 May 2026
··
Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

NEWTOWN, Pa., May 8, 2026, 13:12 Traws Pharma Inc. on Friday announced plans to push ahead with possible clinical candidates targeting hantavirus infections, shifting the antiviral developer’s focus after a lethal outbreak on a cruise ship. The company hasn’t disclosed a frontrunner. Chief Scientific Officer C. David Pauza said Traws “plans to rapidly advance clinical candidates.” Chief Medical Officer Robert R. Redfield described the move as an emergency push for “life-saving treatments.”
8 May 2026
···
Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Prescriptions for Eli Lilly and Company’s new oral weight-loss drug Foundayo reached 3,707 in the U.S. during its second week, according to IQVIA data cited by analysts. That’s behind the early numbers seen for Novo Nordisk’s competing Wegovy pill and has weighed on Lilly shares. In its launch week, Foundayo saw 1,390 prescriptions. This figure is key: investors are watching the launch closely to gauge if Lilly can push past injectables like Zepbound and stay ahead in the obesity drug race. Pills may bring in patients who’d rather skip injections, though Novo already enjoys a head start—time on shelves, brand muscle, momentum.
24 April 2026
···
Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Shares of Hims & Hers Health surged Thursday after the FDA signaled it would review restrictions on certain peptides—a move that’s opened up a new narrative for investors as the telehealth firm shifts focus from promoting compounded GLP-1 drugs. By early afternoon in New York, the stock was changing hands at $26.65, up $2.36 on the day. Timing is crucial for Hims, which overhauled its U.S. weight-loss plan just last month. In March, the company cut out advertising for compounded GLP-1 offerings across its platform and all marketing channels, while at the same time moving to widen access to branded therapies via a deal with Novo Nordisk.
16 April 2026
···
Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly shares grabbed attention Thursday, with the drugmaker reporting its experimental obesity and diabetes therapy, retatrutide, hit the primary endpoint in a late-stage trial—showing notable drops in both weight and blood sugar. The stock last changed hands at $918.05, off 1.3% early, after Tuesday’s nearly 6% tumble that followed a rare downgrade from HSBC. Timing is a factor here. Investors are watching to see if Lilly can keep converting clinical successes into real growth, now that the obesity-drug focus has moved from supply constraints to pricing and reimbursement questions. The cash-pay segment—patients buying out of pocket, without insurance—adds another wrinkle. Lilly is also awaiting a U.S. ruling on orforglipron, its oral obesity candidate. Chief Financial Officer Lucas Montarce said earlier this month the drug was “on track in the US” and could hit the market as soon as the second quarter.
19 March 2026
···
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

NORTH CHICAGO, Illinois, March 10, 2026, 14:19 CDT. AbbVie said on Monday its experimental obesity drug ABBV-295 helped adults lose up to 9.79% of their body weight in 12 weeks in an early-stage study, giving the drugmaker its clearest sign yet that it may have a contender in a market led by Eli Lilly and Novo Nordisk. The company said no serious adverse events were reported.
10 March 2026
····
Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Copenhagen, February 8, 2026, 22:42 CET — The market has closed. Novo Nordisk A/S Class B starts the week with less pressure from copycat concerns, after Hims & Hers said it’s pulling its $49 compounded version of Novo’s Wegovy weight-loss pill. Novo, Hims & Hers, and Eli Lilly are also sinking serious money into Super Bowl ads, all trying to catch more cash-paying U.S. customers.
8 February 2026
···
1 2 3 4

Stock Market Today

  • STARTRADER rolls out pre-IPO CFDs for OpenAI, Anthropic
    June 29, 2026, 9:36 PM EDT. STARTRADER is offering pre-IPO contracts for difference (CFD) products on OpenAI and Anthropic starting June 29, 2026. Traders get 5x leverage and can trade these names 24/7, including weekends. STARTRADER said client demand drove the decision, giving users a way in on these big AI players before their public listings. CEO Peter Karsten said the broker wants to help clients take market positions before shares hit exchanges. With this launch, STARTRADER adds to its batch of themed CFD instruments aimed at retail and institutional investors looking for exposure to private tech.
Go toTop